HRP20180386T1 - Farmaceutski aktivni spojevi - Google Patents
Farmaceutski aktivni spojevi Download PDFInfo
- Publication number
- HRP20180386T1 HRP20180386T1 HRP20180386TT HRP20180386T HRP20180386T1 HR P20180386 T1 HRP20180386 T1 HR P20180386T1 HR P20180386T T HRP20180386T T HR P20180386TT HR P20180386 T HRP20180386 T HR P20180386T HR P20180386 T1 HRP20180386 T1 HR P20180386T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- pharmaceutically acceptable
- solvate
- methyl
- acceptable salt
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 11
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- -1 4-(6-chloro-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- AKJBLKUZXRMECW-UHFFFAOYSA-N 6-chloro-7-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]-2-(1,3-dimethylpyrazol-4-yl)-1h-imidazo[4,5-b]pyridine Chemical compound CC1=NN(C)C=C1C(NC1=NC=C2Cl)=NC1=C2N1CCN(CC=2C=CC(Cl)=CC=2)CC1 AKJBLKUZXRMECW-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (10)
1. Spoj prema dolje prikazanoj formuli I:
[image]
naznačen time da
R1 je Br ili Cl;
R2 je odabran od dolje prikazane formule II ili formule III:
[image]
pri čemu Ra je vodik ili metil;
ili njegove farmaceutski prihvatljive soli ili solvati.
2. Spoj prema zahtjevu 1, naznačen time da R1 je Cl.
3. Spoj prema zahtjevu 1, naznačen time da R1 je Br.
4. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time da R2 je formula II.
5. Spoj prema bilo kojem od zahtjeva 1 do 3, naznačen time da R2 je formula III.
6. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time da je bilo koji od:
6-kloro-7-(4-(4-klorobenzil)piperazin-1-il)-2-(1,3-dimetil-1H-pirazol-4-il)-3H-imidazo[4,5-b]piridin;
3-((4-(6-kloro-2-(1,3-dimetil-1H-pirazol-4-il)-3H-imidazo[4,5-b]piridin-7-il)piperazin-1-il)metil)-1,2,4-oksadiazol;
3-((4-(6-kloro-2-(1,3-dimetil-1H-pirazol-4-il)-3H-imidazo[4,5-b]piridin-7-il)piperazin-1-il)metil)-5-metil-1,2,4-oksadiazol;
ili njihove farmaceutski prihvatljive soli ili solvati.
7. Farmaceutski pripravak naznačen time da sadrži spoj prema bilo kojem od zahtjeva 1 do 6, ili njegovu farmaceutski prihvatljivu sol ili solvat, te jedno ili više farmaceutski prihvatljivih pomoćnih sredstava.
8. Spoj prema bilo kojem od zahtjeva 1 do 6, ili njegova farmaceutski prihvatljiva sol ili solvat naznačen time da je za uporabu u terapiji.
9. Spoj prema bilo kojem od zahtjeva 1 do 6, ili njegova farmaceutski prihvatljiva sol ili solvat naznačen time da je za uporabu za liječenje proliferativnog poremećaja kao što je rak.
10. Spoj za uporabu prema zahtjevu 9, ili njegova farmaceutski prihvatljiva sol ili solvat, naznačen time da proliferativni poremećaj je akutna mijeloidna leukemija.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1211021.9A GB201211021D0 (en) | 2012-06-21 | 2012-06-21 | Pharmaceutically active compounds |
| PCT/GB2013/051633 WO2013190319A1 (en) | 2012-06-21 | 2013-06-21 | Pharmaceutically active compounds |
| EP13731470.4A EP2864328B8 (en) | 2012-06-21 | 2013-06-21 | Pharmaceutically active compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180386T1 true HRP20180386T1 (hr) | 2018-04-20 |
Family
ID=46641296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180386TT HRP20180386T1 (hr) | 2012-06-21 | 2018-03-05 | Farmaceutski aktivni spojevi |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9447092B2 (hr) |
| EP (1) | EP2864328B8 (hr) |
| JP (1) | JP6159397B2 (hr) |
| CN (1) | CN104470922B (hr) |
| AU (1) | AU2013279040B2 (hr) |
| BR (1) | BR112014032142B1 (hr) |
| CA (1) | CA2876357C (hr) |
| CY (1) | CY1120608T1 (hr) |
| DK (1) | DK2864328T3 (hr) |
| ES (1) | ES2660159T3 (hr) |
| GB (1) | GB201211021D0 (hr) |
| HR (1) | HRP20180386T1 (hr) |
| HU (1) | HUE036048T2 (hr) |
| IN (1) | IN2015MN00045A (hr) |
| LT (1) | LT2864328T (hr) |
| NO (1) | NO2864328T3 (hr) |
| PL (1) | PL2864328T3 (hr) |
| PT (1) | PT2864328T (hr) |
| RS (1) | RS56996B1 (hr) |
| RU (1) | RU2654942C2 (hr) |
| SI (1) | SI2864328T1 (hr) |
| WO (1) | WO2013190319A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201522532D0 (en) * | 2015-12-21 | 2016-02-03 | Cancer Rec Tech Ltd | Novel pyrrolo[3,2-c]pyridine-6-amino derivatives |
| JP6591036B2 (ja) | 2016-02-26 | 2019-10-16 | 公益財団法人がん研究会 | Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系 |
| GB2592622B (en) * | 2020-03-04 | 2022-08-03 | Ellipses Pharma Ltd | Formulations of a dual aurora kinase/FLT3 inhibitor |
| GB2596038B (en) * | 2020-03-04 | 2022-12-14 | Ellipses Pharma Ltd | Salts and polymorphic forms of (6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-B]pyridine) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| EP0880508B1 (en) | 1996-02-13 | 2003-04-16 | AstraZeneca AB | Quinazoline derivatives as vegf inhibitors |
| ATE211134T1 (de) | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| KR20030013433A (ko) | 2000-05-31 | 2003-02-14 | 아스트라제네카 아베 | 혈관 손상 활성을 가진 인돌 유도체 |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| AU6623301A (en) | 2000-07-07 | 2002-01-21 | Angiogene Pharm Ltd | Colchinol derivatives as vascular damaging agents |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| WO2003004488A1 (en) * | 2001-07-03 | 2003-01-16 | Chiron Corporation | Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
| TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| EP2251341A1 (en) * | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
| WO2007072017A2 (en) * | 2005-12-22 | 2007-06-28 | The Institute Of Cancer Research | Enzyme inhibitors |
| CN101616920A (zh) * | 2007-01-30 | 2009-12-30 | 比奥根艾迪克Ma公司 | 1-H-吡唑并(3,4b)嘧啶衍生物及其作为有丝分裂激酶调节剂的用途 |
| WO2009001021A1 (en) * | 2007-06-26 | 2008-12-31 | Chroma Therapeutics Ltd. | Imidazopyridine derivatives useful as enzyme inhibitors for the treatment of cell proliferative and autoimmune diseases |
| CA2728559A1 (en) * | 2008-07-03 | 2010-01-07 | Exelixis Inc. | Cdk modulators |
| TWI617560B (zh) * | 2010-09-14 | 2018-03-11 | 伊塞利克斯公司 | PI3Kδ 抑制劑以及其應用和生產方法 |
-
2012
- 2012-06-21 GB GBGB1211021.9A patent/GB201211021D0/en not_active Ceased
-
2013
- 2013-06-21 AU AU2013279040A patent/AU2013279040B2/en active Active
- 2013-06-21 PL PL13731470T patent/PL2864328T3/pl unknown
- 2013-06-21 JP JP2015517858A patent/JP6159397B2/ja active Active
- 2013-06-21 WO PCT/GB2013/051633 patent/WO2013190319A1/en active Application Filing
- 2013-06-21 RU RU2015101702A patent/RU2654942C2/ru active
- 2013-06-21 ES ES13731470.4T patent/ES2660159T3/es active Active
- 2013-06-21 EP EP13731470.4A patent/EP2864328B8/en active Active
- 2013-06-21 HU HUE13731470A patent/HUE036048T2/hu unknown
- 2013-06-21 BR BR112014032142-6A patent/BR112014032142B1/pt active IP Right Grant
- 2013-06-21 NO NO13731470A patent/NO2864328T3/no unknown
- 2013-06-21 CA CA2876357A patent/CA2876357C/en active Active
- 2013-06-21 CN CN201380032901.2A patent/CN104470922B/zh active Active
- 2013-06-21 IN IN45MUN2015 patent/IN2015MN00045A/en unknown
- 2013-06-21 DK DK13731470.4T patent/DK2864328T3/en active
- 2013-06-21 US US14/409,042 patent/US9447092B2/en active Active
- 2013-06-21 PT PT137314704T patent/PT2864328T/pt unknown
- 2013-06-21 RS RS20180267A patent/RS56996B1/sr unknown
- 2013-06-21 SI SI201330965T patent/SI2864328T1/en unknown
- 2013-06-21 LT LTEP13731470.4T patent/LT2864328T/lt unknown
-
2018
- 2018-03-05 HR HRP20180386TT patent/HRP20180386T1/hr unknown
- 2018-03-06 CY CY181100275T patent/CY1120608T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2660159T3 (es) | 2018-03-21 |
| GB201211021D0 (en) | 2012-08-01 |
| EP2864328B1 (en) | 2017-12-06 |
| CN104470922A (zh) | 2015-03-25 |
| EP2864328A1 (en) | 2015-04-29 |
| RS56996B1 (sr) | 2018-05-31 |
| JP2015520222A (ja) | 2015-07-16 |
| JP6159397B2 (ja) | 2017-07-05 |
| LT2864328T (lt) | 2018-04-10 |
| US20150266868A1 (en) | 2015-09-24 |
| AU2013279040B2 (en) | 2017-11-16 |
| CA2876357C (en) | 2020-07-14 |
| PL2864328T3 (pl) | 2018-06-29 |
| RU2015101702A (ru) | 2016-08-10 |
| WO2013190319A1 (en) | 2013-12-27 |
| BR112014032142B1 (pt) | 2022-03-03 |
| AU2013279040A1 (en) | 2015-01-29 |
| NO2864328T3 (hr) | 2018-05-05 |
| DK2864328T3 (en) | 2018-03-12 |
| IN2015MN00045A (hr) | 2015-10-16 |
| CY1120608T1 (el) | 2019-12-11 |
| SI2864328T1 (en) | 2018-04-30 |
| RU2654942C2 (ru) | 2018-05-25 |
| BR112014032142A2 (pt) | 2017-06-27 |
| CA2876357A1 (en) | 2013-12-27 |
| US9447092B2 (en) | 2016-09-20 |
| PT2864328T (pt) | 2018-03-12 |
| CN104470922B (zh) | 2016-08-24 |
| EP2864328B8 (en) | 2018-01-24 |
| HUE036048T2 (hu) | 2018-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180386T1 (hr) | Farmaceutski aktivni spojevi | |
| HRP20201949T1 (hr) | 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji | |
| HRP20161674T1 (hr) | 4-(8-METOKSI-1-((1-METOKSIPROPAN-2-IL)-2-(TETRAHIDRO-2H-PIRAN-4-IL)-1H-IMIDAZO[4,5-c]KINOLIN-7-IL)-3,5-DIMETILIZOKSAZOL I NJEGOVA UPOTREBA KAO INHIBITORA BROMODOMENE | |
| HRP20191268T1 (hr) | Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk | |
| HRP20170311T1 (hr) | Novi spojevi pirolopirimidina kao inhibitori protein kinaza | |
| PL3357922T3 (pl) | Pochodne 2-((5-(1-(3-(metylosulfonylo)propylo)piperydyn-4-ylo)pirydyn-2-ylo)amino)pirydo[2,3-d]pirymidyn-7(8h)-onu i związki pokrewne jako inhibitory cdk4 do leczenia nowotworów | |
| CO2018002829A2 (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) | |
| JP2016523270A5 (hr) | ||
| GEP20156417B (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases | |
| JP2014505735A5 (hr) | ||
| MX2015012432A (es) | Inhibidores piridinicos de la cinasa cdk9. | |
| HRP20171824T1 (hr) | (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI S DVOJNOM AKTIVNOŠĆU INVERZNIH AGONISTA H1 I ANTAGONISTA 5-HT2A | |
| IL231226A (en) | Compounds and preparations as kinase c-kit inhibitors, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of diseases | |
| JP2014513139A5 (hr) | ||
| JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
| WO2013004995A8 (en) | Pyrimidinone compounds and their use | |
| WO2014070991A3 (en) | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists | |
| PH12016501624A1 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| MY161236A (en) | (pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nachr | |
| MX340574B (es) | Imidazo pirazinas. | |
| TN2016000061A1 (en) | Amide derivatives as lysophosphatidic acid receptor antagonists | |
| AR084731A1 (es) | Derivados de imidazoquinolina sustituidos | |
| WO2016010869A3 (en) | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | |
| EP2796450A4 (en) | 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES | |
| PH12017501121B1 (en) | Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors |